Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027

Caribou Biosciences, Inc.

GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.
Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.
Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.
CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.